State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Beijing Institute of Biomedine, Beijing, 100091, China.
Eur J Med Chem. 2018 Oct 5;158:548-558. doi: 10.1016/j.ejmech.2018.09.015. Epub 2018 Sep 8.
Penicimutanolones A (1) and B (2), penicimutanolone A methyl ether (3), and penicimumide (4), four new antitumor metabolites, were isolated from a neomycin-resistant mutant of the marine-derived fungus Penicillium purpurogenum G59. The structures of the compounds were elucidated by spectroscopic methods, and the absolute configurations were determined by X-ray crystallography and calculated ECD. In MTT and SRB assays, compounds 1-3 showed strong inhibitory effects on 14 human cancer cell lines. Compounds 1 and 2 maybe induce apoptosis of cancer cells mainly due to the inhibition of the expression of survivin, a client protein of HSP90. In addition, in vivo antitumor activity was observed for compound 1 in murine sarcoma HCT116 tumor-bearing Kunming mice, using docetaxel as a positive control.
Penicimutanolones A (1) 和 B (2)、penicimutanolone A 甲醚 (3) 和 penicimumide (4) 是从海洋来源真菌青霉属 purpurogenum G59 的新霉素抗性突变株中分离得到的四种新型抗肿瘤代谢产物。通过光谱方法阐明了化合物的结构,并通过 X 射线晶体学和计算 ECD 确定了它们的绝对构型。在 MTT 和 SRB 测定中,化合物 1-3 对 14 种人癌细胞系表现出强烈的抑制作用。化合物 1 和 2 可能主要通过抑制 HSP90 的客户蛋白 survivin 的表达诱导癌细胞凋亡。此外,在荷有鼠肉瘤 HCT116 的昆明小鼠中,以多西紫杉醇为阳性对照,观察到化合物 1 的体内抗肿瘤活性。